Houston Oncology Summit: Talking KRAS & pan-RAS inhibition with MD Anderson’s Ferdinandos Skoulidis
Ferdinandos Skoulidis describes improvements being made to G12C inhibitors and why he believes the theoretical potential for pan-RAS inhibitors is substantial.
Brought to you by:
